MFSD13A

Across TCGA pan-cancer cohorts, MFSD13A mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MFSD13A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MFSD13A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MFSD13A is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where MFSD13A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MFSD13A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+1.225	<.001	9	view →
LUAD	Male	II,III,IV	+0.806	.008	3	view →
LSCC	Female	II,III,IV	−0.445	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MFSD13A–CCRCC

Open the CCRCC breakdown →